Invitation to presentation of Cantargia’s report for the fourth quarter of 2021 on February 24 at 3.00 p.m. CET

Cantargia AB will publish the company’s report for the fourth quarter for 2021 on Thursday, February 24, 2022, at 08.30 a.m. CET.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on February 24, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the fourth quarter 2021, followed by a Q&A-session.

The conference call can be followed at: https://tv.streamfabriken.com/cantargia-q4-2021

To attend through telephone, please dial-in at one of the numbers below:

SE: +46850558374
UK: +443333009274
US: +16467224903

The webcast will also be available on demand on Cantargia’s corporate website: https://cantargia.com

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This information was submitted for publication, at 13.00 CET on 8 February 2022.

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main project, the antibody nadunolimab, is being studied clinically in combination with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

---